Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2016-06-30 17:46:14
Reporting Period:
Filing Date:
Accepted Time:
2016-06-30 17:46:14
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1609809 Seres Therapeutics Inc. MCRB Pharmaceutical Preparations (2834) 274326290
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1643734 D. Eric Shaff C/o Seres Therapeutics, Inc.
200 Sidney Street
Cambridge MA 02139
Cfo And Evp No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-06-30 4,533 $7.79 4,533 No 4 M Direct
Common Stock Disposition 2016-06-30 4,533 $29.54 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2016-06-30 4,533 $0.00 4,533 $7.79
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
233,454 2024-12-08 No 4 M Direct
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted on February 26, 2016 by the Reporting Person.
  2. The option vested as to 25% of the shares subject to the option on November 17, 2015, and has vested or will vest as to an additional 6.25% of the total number of shares subject to the option upon the completion of each three consecutive months of service thereafter.